SCI Pharmtech, Inc. (TPE:4119)
Taiwan
· Delayed Price · Currency is TWD 78.30
+0.30 (0.38%)
Apr 2, 2025, 1:35 PM CST
SCI Pharmtech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,524 | 1,204 | 899.74 | 864.22 | 2,689 | Upgrade
|
| Revenue Growth (YoY) | 26.54% | 33.83% | 4.11% | -67.86% | 14.16% | Upgrade
|
| Cost of Revenue | 1,113 | 853.84 | 608.56 | 656.13 | 1,415 | Upgrade
|
| Gross Profit | 410.67 | 350.32 | 291.18 | 208.09 | 1,274 | Upgrade
|
| Selling, General & Admin | 169.7 | 140.93 | 132.56 | 104.08 | 180.56 | Upgrade
|
| Research & Development | 42.68 | 49.09 | 39.65 | 30.35 | 43.37 | Upgrade
|
| Operating Expenses | 212.38 | 190.02 | 172.21 | 134.43 | 222.75 | Upgrade
|
| Operating Income | 198.29 | 160.3 | 118.97 | 73.66 | 1,052 | Upgrade
|
| Interest Expense | -5.54 | -6.29 | -1.07 | -0.04 | -0.04 | Upgrade
|
| Interest & Investment Income | 9.98 | 6.17 | 6.49 | 10.04 | 12.65 | Upgrade
|
| Earnings From Equity Investments | -23.73 | -13.84 | -12.56 | -13.55 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 22.6 | 2.37 | 27.55 | -15 | -30.63 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.19 | 6.62 | 4.37 | 24.41 | 4.14 | Upgrade
|
| EBT Excluding Unusual Items | 211.79 | 155.33 | 143.75 | 79.52 | 1,038 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.62 | -1.87 | -14.07 | 2.24 | -15.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.58 | -1.33 | - | - | Upgrade
|
| Other Unusual Items | - | 0.37 | 101.2 | -16.26 | -1,086 | Upgrade
|
| Pretax Income | 646.86 | 364.19 | 387.82 | 65.51 | 455.22 | Upgrade
|
| Income Tax Expense | 112.18 | 69.47 | 79.04 | 9.81 | 95.09 | Upgrade
|
| Net Income | 534.68 | 294.72 | 308.78 | 55.7 | 360.12 | Upgrade
|
| Net Income to Common | 534.68 | 294.72 | 308.78 | 55.7 | 360.12 | Upgrade
|
| Net Income Growth | 81.42% | -4.55% | 454.40% | -84.53% | -36.94% | Upgrade
|
| Shares Outstanding (Basic) | 120 | 109 | 107 | 107 | 107 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 110 | 108 | 108 | 108 | Upgrade
|
| Shares Change (YoY) | 9.44% | 1.87% | 0.08% | -0.49% | -0.26% | Upgrade
|
| EPS (Basic) | 4.47 | 2.70 | 2.88 | 0.52 | 3.36 | Upgrade
|
| EPS (Diluted) | 4.46 | 2.69 | 2.87 | 0.52 | 3.33 | Upgrade
|
| EPS Growth | 65.80% | -6.27% | 456.63% | -84.53% | -36.80% | Upgrade
|
| Free Cash Flow | -86.12 | -813.59 | -871.02 | -490.75 | 753.83 | Upgrade
|
| Free Cash Flow Per Share | -0.72 | -7.42 | -8.10 | -4.57 | 6.98 | Upgrade
|
| Dividend Per Share | 1.500 | 1.250 | 0.222 | - | 0.370 | Upgrade
|
| Dividend Growth | 20.00% | 462.56% | - | - | -91.38% | Upgrade
|
| Gross Margin | 26.95% | 29.09% | 32.36% | 24.08% | 47.39% | Upgrade
|
| Operating Margin | 13.01% | 13.31% | 13.22% | 8.52% | 39.10% | Upgrade
|
| Profit Margin | 35.09% | 24.47% | 34.32% | 6.44% | 13.39% | Upgrade
|
| Free Cash Flow Margin | -5.65% | -67.56% | -96.81% | -56.79% | 28.03% | Upgrade
|
| EBITDA | 429.73 | 303.68 | 207.95 | 135.59 | 1,183 | Upgrade
|
| EBITDA Margin | 28.20% | 25.22% | 23.11% | 15.69% | 43.98% | Upgrade
|
| D&A For EBITDA | 231.44 | 143.38 | 88.98 | 61.93 | 131.25 | Upgrade
|
| EBIT | 198.29 | 160.3 | 118.97 | 73.66 | 1,052 | Upgrade
|
| EBIT Margin | 13.01% | 13.31% | 13.22% | 8.52% | 39.10% | Upgrade
|
| Effective Tax Rate | 17.34% | 19.07% | 20.38% | 14.98% | 20.89% | Upgrade
|
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.